Develops a genetically modified bacterial delivery platform for immuno-oncology that locally activates immune signaling inside tumors to turn “cold” tumors “hot” while limiting systemic immune exposure. Lead candidate delivers constitutively active STING and IL-15plex to the tumor microenvironment to engage both innate and adaptive anti-tumor immunity.